Global Genetic COPD Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Genetic COPD Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
For some people, their COPD is actually related to a rare genetic condition called alpha1-antitrypsin deficiency, or alpha-1 for short. This condition is sometimes referred to as "genetic COPD," and is caused by a deficiency in a specific protein called alpha1-antitrypsin.
Genetic COPD report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Genetic COPD market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Genetic COPD industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Genetic COPD key companies include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc. Pfizer, Baxter, AstraZeneca are top 3 players and held % share in total in 2022.
Genetic COPD can be divided into Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB) and Other, etc. Augmentation Therapy is the mainstream product in the market, accounting for % share globally in 2022.
Genetic COPD is widely used in various fields, such as Hospitals, Specialty Clinics, Pharmacies and Others, etc. Hospitals provides greatest supports to the Genetic COPD industry development. In 2022, global % share of Genetic COPD went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Genetic COPD market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Genetic COPD market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Genetic COPD introduction, etc. Genetic COPD Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Genetic COPD market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Genetic COPD report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Genetic COPD market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Genetic COPD industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Genetic COPD key companies include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc. Pfizer, Baxter, AstraZeneca are top 3 players and held % share in total in 2022.
Genetic COPD can be divided into Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB) and Other, etc. Augmentation Therapy is the mainstream product in the market, accounting for % share globally in 2022.
Genetic COPD is widely used in various fields, such as Hospitals, Specialty Clinics, Pharmacies and Others, etc. Hospitals provides greatest supports to the Genetic COPD industry development. In 2022, global % share of Genetic COPD went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Genetic COPD market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Genetic COPD market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Genetic COPD introduction, etc. Genetic COPD Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Genetic COPD market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices